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Abstract
The RAS signaling pathway is involved in the regulation of developmental processes, including cell growth,
proliferation, and differentiation, in the central nervous system (CNS). Germline mutations in the RAS signaling
pathway genes are associated with a group of neurodevelopmental disorders, collectively called RASopathy, which
includes neurofibromatosis type 1, Noonan syndrome, cardio-facio-cutaneous syndrome, and Costello syndrome.
Most mutations associated with RASopathies increase the activity of the RAS-ERK signaling pathway, and therefore,
most individuals with RASopathies share common phenotypes, such as a short stature, heart defects, facial
abnormalities, and cognitive impairments, which are often accompanied by abnormal CNS development. Recent
studies using mouse models of RASopathies demonstrated that particular mutations associated with each disorder
disrupt CNS development in a mutation-specific manner. Here, we reviewed the recent literatures that investigated
the developmental role of RASopathy-associated mutations using mutant mice, which provided insights into the
specific contribution of RAS-ERK signaling molecules to CNS development and the subsequent impact on cognitive
function in adult mice.
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Introduction
The RAS-extracellular signal-regulated kinase (ERK)
pathway is a highly conserved signaling cascade that
transduces signals from membrane receptors to the
cytoplasm and nucleus by protein–protein interactions
and phosphorylation [1–3]. It plays a critical role in con-
trolling various cellular processes, including cell growth,
survival, proliferation, and differentiation, in developing
and adult tissues, such as the brain [2, 4]. RAS, which is
composed of a multigene family that includes HRAS,
KRAS, and NRAS, encodes a small guanosine nucleotide-
bound GTPase protein, and the activation of the RAS-
ERK signal transduction is initiated by the binding of
growth factors to G-protein-coupled receptors, such as
receptor tyrosine kinases (RTKs) and cytokine receptors.
RAS is activated by guanine nucleotide exchange factors
(GEFs), such as SOS1, whose activity is regulated by
multiple adaptor proteins, including GAB1 and GRB2
(Fig. 1) [5]. On the contrary, GTPase activating proteins
(GAPs), such as NF1, switch RAS activity off by hydro-
lyzing GTP to GDP. The GTP-bound form of active
RAS leads to the activation of its direct downstream ef-
fector, RAF. RAF encodes a serine/threonine kinase and
represents the RAF family, which also includes ARAF,
BRAF, and RAF1. RAF phosphorylates and activates the
MAPK kinase, MAPK/ERK kinase 1/2 (MEK1/2), which
in turn activates ERK1 and ERK2 by phosphorylating the
tyrosine and threonine residues on ERK1/2 [6]. ERK1
and ERK2 are homologous subtypes of the ERK family
and are final effectors of the RAS-ERK pathway. ERK1/2
affect a large number of downstream molecules, such as
nuclear components, transcription factors, and mem-
brane proteins [7].
Since the RAS-ERK pathway is critically involved in mul-
tiple biological processes, germline mutations in RAS-ERK
signaling components can cause a class of developmental
disorders that are collectively called RASopathy [3, 8, 9].
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RASopathy affects approximately 1 in 1,000 live births
worldwide and shares a common molecular mechanism,
such as mutations in RAS-ERK signaling components [4].
Representatively, RASopathy includes 1) neurofibromatosis
type 1, which is caused by loss of function mutations in
NF1; 2) Noonan syndrome, caused by gain of function mu-
tations in PTPN11, SOS1, SHOC2, CBL, KRAS, NRAS,
BRAF, RAF1, and MEK1; 3) Noonan syndrome with mul-
tiple lentigines that is caused by mutations in PTPN11 and
RAF1; 4) cardio-facio-cutaneous syndrome, which is caused
by either gain of function or loss of function mutations in
BRAF, KRAS, MEK1, and MEK2; 5) Costello syndrome,
caused by gain of function mutations in HRAS; and 6)
neurofibromatosis type 1-like syndrome (NFLS or Legius
syndrome) that is also caused by loss of function mutations
in NF1. RASopathies share typical characteristics, such as a
short stature, craniofacial dysmorphism, cardiac defects,
and neurocognitive impairments that are accompanied by
abnormal brain development [10]. However, each RASopa-
thy also displays distinct and unique symptoms, depending
on the mutated genes [3, 11]. Consistently, recent studies
using mouse models of RASopathies have demonstrated
that each disorder also shows disease-specific abnor-
malities in central nervous system (CNS) develop-
ment. Here, we review the distinctive roles of RAS-
ERK signaling molecules in CNS development that
were revealed by investigating the deficits in CNS develop-
ment of RASopathies (Tables 1 and 2). Furthermore, we
also review how RASopathy-associated mutations affect
cognitive function in mice and human.
RAS-ERK signaling and nervous system development
The RAS-ERK signaling pathway is tightly regulated dur-
ing CNS development and many studies have demon-
strated that the dysregulation of this signaling pathway
results in aberrant brain development. There are a num-
ber of studies demonstrating that ERK1/2, the final ef-
fectors of RAS-ERK signaling, are involved in cell
proliferation and differentiation in the nervous system
[110]. Activation of ERK signaling is required for neural
stem cells (NSCs) to maintain their ability to self-renew
and form neurospheres, indicating that ERK may act as
a critical regulator in the maintenance of NSCs [111]. In
addition, it has also been shown that ERK signaling
Fig. 1 The RAS-ERK signaling pathway and associated disorders. A simplified RAS-ERK signaling pathway. Genes frequently mutated in RASopathy
are colored based on the RASopathy and are displayed as a polygon depending on their functional categories. NS/NSML, Noonan syndrome/
Noonan syndrome with multiple lentigines; NF1, Neurofibromatosis type 1; CS, Costello syndrome; CFCS, Cardio-facio-cutaneous syndrome; GEF,
guanine exchange factor; GAP, GTPase activating protein.
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promotes neuronal survival by multiple mechanisms
[112, 113]. For example, an ERK-activated kinase, ribo-
somal S6 Kinase (RSK), phosphorylates the pro-
apoptotic protein BAD and suppresses BAD-mediated
apoptosis in neurons [112]. ERK was also shown to regu-
late the activation of anti-apoptotic regulators, such as
Bcl-2, CREB, and STAT3/5, and subsequently promote
cell survival [112, 114, 115]. However, in spite of the
crucial role of ERK in neuronal survival, aberrant and
long-lasting ERK activation has also been implicated in
neurodegenerative diseases [116, 117].
Several studies have implied that the MEK/ERK signal-
ing cascade has a crucial role in neurogenesis. ERK2 is ne-
cessary for regulating the proliferation of neurogenic
precursors and the positive regulation of neurotrophin-
induced neurogenesis by the MEK-C/EBP pathway during
cortical development [118, 119]. Despite the evidence that
MEK is required for neurogenesis, in vivo and in vitro
studies have demonstrated that ERK also regulates and
maintains the pool of glial populations in the developing
brain [109]. NSC-specific ablation of Mek1/2 induces a
complete blockade of glial specificity and gliogenesis fail-
ure, while Mek1 gain of function promotes precocious
glial progenitor specification in mice [109]. Several studies
have demonstrated that in vitro, Erk1 and Erk2 are critical
components of proliferation in cultured rat astrocytes, and
that MEK/ERK signaling induces gliogenic signals, such as
SDF-1a and FGF2 [120–122]. Consistently, treatment with
the MEK inhibitor PD98059 induced a reduction in astro-
cytic growth, suggesting that MEK/ERK signaling is in-
volved in astrocyte proliferation [122]. In addition, the
chemical inhibition of MEK also impairs the ability of
oligodendrocyte precursors to differentiate into mature
oligodendrocyte in vitro, suggesting that both oligoden-
drocytes and astrocytes are regulated by ERK signaling
[103]. Several studies demonstrated that the pharmaco-
logical inhibition of ERK1/2 signaling in oligodendrocyte
progenitors negatively regulates differentiation and the
transition of early progenitors to late oligodendrocyte pro-
genitors [123–125]. Furthermore, ERK signaling promotes
oligodendrocyte myelination [126]. However, there are
conflicting results about the role of ERK signaling in the
differentiation of oligodendrocyte progenitors into mature
oligodendrocytes. Recently, Suo and colleagues demon-
strated that MEK inhibitors significantly enhance the dif-
ferentiation of oligodendrocyte precursor cells into
oligodendrocytes in vitro and in vivo [127]. Consistently,
many studies have suggested that increased ERK activity
negatively regulates oligodendrocyte differentiation. For
example, ERK1/2 activation, which is induced by high
dose stimulation of neuregulin-1 or fibroblast growth
factor-2 in mature oligodendrocytes, results in downregu-
lated myelin proteins and aberrant cell cycle re-entry
[128–130].
The RAS-ERK signaling pathway also regulates the ex-
pression of transcription factors, such as cell fate determi-
nants. Numerous studies demonstrated that the enhanced
activity of RAS-ERK signaling induces the expression of
the transcription factor OLIG2, which promotes the fate
of NSCs to the glial lineage [85, 90, 108]. Furthermore, the
activation of RAS-ERK signaling promotes the expression
of the pro-neural gene Achaete scute-like 1 (Ascl1) but
blocks pro-neural gene Neurogenin 2 (Neurog2) expres-
sion. Neurog2 specifies glutamatergic neuronal cell fate in
dorsal progenitors, while Ascl1 specifies neocortical
gamma-aminobutyric acidergic (GABAergic) neurons and
Table 1 Human patients with RASopathies and their phenotypes
Disease Associated genes CNS structural phenotypes Other phenotypes
Neurofibromatosis type 1 NF1 (95%) [12] Neurofibromas , abnormal cortical
development [13], abnormal glial
development [14], macrocephaly
Below-average IQ, ADHD, impaired
executive functioning, deficits in
visual-spatial skills [15, 16],
hyperpigmentation of melanocytes,
hamartomas of the iris [17, 18], bone




PTPN11 (>50%) [21], RAF1
(3-17%) [22, 23], SOS1
(9-13%) [24] KRAS (<2%)
[25, 26], BRAF (<2%) [22],
MEK1/2 (<2%) [27]
Cerebellar ectopia [28, 29], temporal
lobe anomaly, hydrocephalus,
cerebral abscess [30–32], epilepsy,
cortical dysplasia [33]
Neurocognitive delay [33–35], typical
facial abnormalities, short stature,
motor delay, increased risk of




MEK1/2 (7-11%) [42, 43],
KRAS (5-8%) [25, 43]
Ventriculomegaly, hydrocephalus
[44–50], atrophy [44, 46, 51–54],
migration and myelination
abnormalities, agenesis of
corpus callosum [50, 52, 55–57]
Neurological abnormalities, seizures,
tactile defensiveness, learning
disabilities [4, 50, 55], craniofacial
defects, cardiac defects [4, 58, 59],
motor delay, hypotonia [4, 50, 55]
Costello syndrome HRAS (85-90%) [60–62],




cerebral malformations [64, 65, 67–71],
cerebellar abnormalities [66, 69, 71–74],
macrocephaly [59, 60]
Mental retardation [59, 60], facial
features, loose skin, severe failure
to thrive, predisposition to
tumors [59, 60]
IQ Intelligence quotient, ADHD Attention deficit hyperactivity disorder;
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Table 2 RASopathy mouse models and their phenotypes
Gene Mouse model CNS structural phenotypes Other phenotypes
Nf1 Nf1 homozygous knockout Defects in the neural tube, hyperplasia of
neural crest-derived ganglia [75]
Embryonic lethality, heart defects, delay in
organ development [76, 77]
Nf1 heterozygous knockout Increased number of astrocytes [78, 79] Impaired synaptic plasticity, impaired spatial
learning, heart defects [80–82]
Synapsin 1-dependent Nf1 ablation Reduced size and weight of the forebrain,
reduced cortical thickness, increased
astrogliogenesis [83]
Learning deficits, growth retardation [83, 84]
hGFAP-dependent Nf1 ablation Increased gliogenesis, enlarged
cerebral cortex, defective GNP
migration and proliferation
[85–88]
Postnatal lethality, growth retardation
[86, 87]





Unlocked latent oligodendrocyte lineage,
defective GNP proliferation and migration,




Ptpn11 Nestin-dependent Ptpn11 ablation Decreased neural stem cell proliferation,
lamination defects, reduced number of
neurons, increased number of astrocytes [92]
Postnatal lethality, growth retardation [92]
Olig1-dependent Ptpn11 ablation Decreased number of oligodendrocyte
precursors and mature oligodendrocytes,
reduced axonal myelination [93]
Developmental abnormalities [93]
Olig2-dependent Ptpn11 ablation Decreased number of oligodendrocyte
precursors, hypomyelination [94]
Postnatal lethality, severe shivering [94]
Olig2-dependent Ptpn11Q79R
knock-in
Increased number of oligodendrocyte




Hydrocephalus, aberrant development of
ependymal cells, reduced proliferation,
enhanced glial differentiation [95]
Postnatal lethality, dome-shaped head,
reduced anxiety behavior, hyperactivity,
impaired motor function [95]
Ptpn11D61G herozygous knock-in Increased neurogenesis, decreased
gliogenesis [96]
Impaired synaptic plasticity, impaired spatial




Enhanced GABAergic synaptogenesis [99] Increased inhibitory tone, impaired spatial
learning [99]
Hras HrasG12V homozygous knock-in Hypertrophy of the brain and pyramidal
neurons [100]




Increase in docked vesicles [101] Increased synaptic plasticity, enhanced
spatial learning [101]
Braf Nestin-dependent Braf ablation Impaired neuronal differentiation,
dysmyelination, defective oligodendrocyte
differentiation [102, 103]
Postnatal lethality, growth retardation,
defective motor coordination, neuromuscular
defects [102, 103]
BrafV600E heterozygous knock-in Increased number of GFAP positive cells in
the DG [104]
Reduced life span, growth retardation, facial
dysmorphia, cardiomegaly, epileptic
seizures [104]
Raf1 Raf1 heterozygous knockout Small granule cell volume, increased cell
death, reduced neuronal maturation [105]
Postnatal lethality, growth retardation,
apoptosis in the lung and liver, limbs
coordination problems [106]
Raf1L613V heterozygous knock-in Increased density of astrocytes, enhanced
OPCs density [107]
Enhanced learning and memory [107]
Mek1/2 Mek1Y130C homozygous knock-in Increased astrocyte density, increased
number of cortical oligodendrocytes [108]
Pulmonary artery stenosis, cranial
dysmorphia [108]
Nestin-dependent Mek1/2 ablation Decrease of astrocyte precursors and OPCs,
failure of gliogenesis [109]
Early postnatal lethality [109]
hGFAP-dependent Mek1/2 ablation Suppressed generation of astrocyte
precursors and OPCs, failure of
gliogenesis [109]
Postnatal lethality [109]
hGFAP-dependent Mek1S218E,S222E Increase in astrocyte precursors and mature
astrocytes, reduction of neuron number [109]
Not described
hGFAP Human glial fibrillary acidic protein, BLBP Brain lipid binding protein, GNP Granule neuron progenitor, DG Dentate gyrus, OPCs Oligodendrocyte
progenitor cells
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oligodendrocyte precursor cells [131–133]. Therefore,
during normal early developmental stages, RAS-ERK sig-
naling activity is kept low so that Neurog2 is able to pro-
mote glutamatergic neuronal differentiation of embryonic
cortical progenitors. However, in an abnormal context
where the RAS-ERK signaling is elevated, Neurog2 expres-
sion is switched to Ascl1 expression [134]. During moder-
ate activation of RAS-ERK signaling, Ascl1 expression
promotes GABAergic neuronal differentiation, while Ascl1
promotes proliferative glioblast phenotypes when RAS-
ERK signaling is highly active [134].
RAS interacts with and regulates other signaling path-
ways in addition to the MEK/ERK cascade. As one of the
main effector pathways of RAS, the phosphatidylinositol
3-kinase (PI3K)-AKT pathway regulates protein synthesis
and variety of cellular processes such as cell growth, cycle
entry, and cellular survival [135–137]. The Ras and PI3K-
AKT pathway were shown to activate and inhibit each
other via multiple cross-talks [138]. Studies using rodent
models have reported distinct phenotypes and revealed a
pivotal role of PI3K signaling in nervous systems. For in-
stance, deleting a PI3K isoform PI3Kγ in mice impaired
synaptic plasticity and behavioral flexibility, while its over-
expression through viral vector resulted in impaired syn-
aptic plasticity and spatial learning [139, 140]. The Janus
kinase (JAK)-signal transducer and activator of transcrip-
tion (STAT) pathway is also a well characterized cascade
known to interact with RAS-ERK [141]. JAK activation
stimulates cell proliferation, differentiation, cell migration
and apoptosis, and there are compelling evidences that
JAK-STAT pathway plays essential roles in synaptic plasti-
city [142].
RASopathies and central nervous system development
Neurofibromatosis type 1
Neurofibromatosis type 1 (NF1) is a relatively common
developmental disease that affects 1 in 3,000 individuals
and is diagnosed by both somatic and behavioral symptoms
[20, 143]. NF1 is caused by loss of function mutations in
NF1 alleles [10, 143, 144]. The NF1 gene encodes a GAP
for RAS, neurofibromin, which promotes the conversion of
active RAS-GTP to inactive RAS-GDP, thus, negatively
regulating the RAS-ERK signaling pathway [145, 146].
Therefore, loss of function mutations in NF1 result in the
hyperactivation of RAS-ERK signaling. As mutations in the
NF1 gene lead to abnormal cell growth, proliferation, and
differentiation, individuals with NF1 frequently display
neurofibromas, hyperpigmentation of melanocytes, and
hamartomas of the iris [17, 18]. Additionally, common fea-
tures of NF1 include bone malformations, cardiac defects,
and neurocognitive impairments [19, 20]. More than 75%
of NF1 patients suffer from cognitive deficits, such as
below-average IQ and specific deficits in attention, execu-
tive functioning, and visual-spatial skills [15, 16].
Although tumor development in the peripheral ner-
vous system is a hallmark of NF1, a variety of CNS ab-
normalities, including neurofibroma, have been reported
in NF1 patients [147]. For example, abnormal cortical
lamination and a compressed cerebral cortex were ob-
served in the brains of NF1 patients, indicating a critical
role for NF1 in cortical development [13]. Interestingly,
several studies have also suggested that NF1 is associated
with deficits in glial development. For example, children
with NF1 display abnormalities in astrocyte growth regu-
lation and tend to develop astrocytoma [14, 148]. Simi-
larly, a postmortem study reported that three NF1
brains exhibited extensively increased astrogliogenesis
[149]. Specifically, an association between an enlarged
corpus callosum and severe learning disabilities in a sub-
population of NF1 patients has been reported [150, 151].
Moore and colleagues also reported that the total brain
volume, especially the gray matter, was significantly lar-
ger in NF1 subjects than in children and adolescents
without NF1. The gray matter volume in NF1 subjects
was inversely correlated with their degree of learning
disability [150]. Taken together, individuals with NF1
display CNS developmental abnormalities, including
promoted astrogliogenesis and structural malformation,
which might be associated with learning disabilities.
Nf1 homozygous knockout mice (Nf1-/-) die in utero
because of severe heart malformations, a delay in renal,
hepatic, and skeletal muscle development, and hyperpla-
sia of neural crest-derived sympathetic ganglia [76, 77].
In addition, Nf1-deficient mouse embryos exhibit defects
in the neural tube, including exencephaly or the thinning
of the dorsal telencephalic wall, although the targeted al-
lele in this study was slightly different from previous in-
vestigations [75]. Therefore, a heterozygous knockout
mouse line (Nf1+/-) has been extensively used to investi-
gate the cellular mechanisms underlying NF1 etiology
[80, 81, 83, 84, 152, 153]. Silva and colleagues showed
that Nf1+/- mice display impaired spatial learning and
impaired hippocampal synaptic plasticity [80, 81]. Mech-
anisms underlying the deficits in learning and synaptic
plasticity in NF1 mouse models have been extensively
reviewed in previous publications [8, 154]. In line with
human patients, Nf1 heterozygous mutant mice showed
developmental abnormalities in the heart and neural
crest-derived tissues, and an increased number of astro-
cytes with high levels of glial fibrillary acidic protein
(GFAP) in the periaqueductal grey, nucleus accumbens,
and hippocampus [76, 79].
Ablation of Nf1 only in neurons by using the Synapsin
I promoter (Nf1Syn1) led to growth retardation, including
reduced body weight and size, that was sustained into
adulthood [83]. Nf1Syn1 conditional knockout (CKO)
mice exhibited reduced size and weight of the forebrain,
but not other brain regions [83]. Histological analyses of
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CKO mice also revealed remarkable defects in the cere-
bral cortex, such as a reduction in cortical thickness
[83]. Neuronal loss in mutant cortices was not detected;
however, interestingly, CKO mice displayed extensive
GFAP immunoreactivity throughout the cerebral cortex,
hippocampus, and brainstem, which indicates increased
astrogliogenesis [83]. These results indicate that Nf1 has
an indispensable role in CNS development, and that
Nf1-deficient neurons induce astroglial hypertrophy and
GFAP induction through a paracrine effect [83, 155].
Several studies suggested that neurofibromin might be
required for NSCs or neuroglial progenitor function, and
that Nf1 mutations affect both astroglial and neuronal lin-
eages. Studies using a well-characterized human GFAP
(hGFAP)-Cre transgenic mouse line have demonstrated
that Nf1 plays a critical role in CNS development. Typic-
ally, hGFAP-Cre expression is first detected in radial glia,
which give rise to both neuronal and glial lineage cells,
around embryonic day 13 [156]. Mutant Nf1hGFAP CKO
mice, which lack neurofibromin in the majority of their
cortical neurons and astrocytes, were born in normal
numbers, but became noticeably smaller than their litter-
mates over time, and typically died by four months of age
[86, 87]. Nf1hGFAP CKO mice displayed enlarged cerebral
cortices and an increased brain to body weight ratio
caused by the enlarged cortex [85, 88]. The mutant mice
also exhibited a notably smaller cerebellum, compared
with littermates, and defective migration and proliferation
of granule neuron progenitors [88]. In addition, Nf1hGFAP
CKO mice failed to form cortical barrels in the somato-
sensory cortex, although segregation of thalamic axons
within the somatosensory cortex was unaffected [87].
Consistent with NF1 patients, the mutant mice displayed
increased GFAP-positive astrocytes throughout both the
gray and the white matter, including the corpus callosum
and anterior commissure [86]. Wang and colleagues also
showed that the Nf1hGFAP CKO mice display increased
gliogenesis at the expense of neurogenesis in the neonatal
period and during adulthood [85]. Due to the altered ratio
of glia to neurons, Nf1hGFAP CKO mice displayed a smaller
olfactory bulb and an enlarged corpus callosum, providing
a link between brain structural abnormalities and cogni-
tive impairments in animal models and those seen in NF1
patients [85]. Similarly, Nf1 inactivation in neuroglial pro-
genitors using a brain lipid binding protein (BLBP)-Cre
mouse strain also led to increased glial proliferation and
abnormal neuronal differentiation in vivo [89]. However,
it is also noteworthy to mention that deleting Nf1 using
GFAP-Cre did not impair either learning or synaptic plas-
ticity in adult mice [84].
Recent studies reported that Nf1 regulates cell fate
specificity and cellular processes in both the develop-
mental stage and in adulthood. Inactivation of Nf1 in
adult NSCs unlocked a latent oligodendrocyte lineage
and allowed NSCs to produce all three lineages in vivo
[90]. Similarly, postnatal Nf1 ablation using Nestin-
CreERT2 was sufficient to cause cerebellar abnormal-
ities, including defective cerebellar foliation, granule
neuron progenitors (GNPs) proliferation, and migration
[88]. Also, deletion of Nf1 in adult hippocampal neural
progenitor cells led to enhanced proliferation and an in-
crease in new neurons in the dentate gyrus [91].
Since Nf1 also functions as a tumor suppressor gene,
in vitro studies in various cell types have suggested that
Nf1 mutations are associated with growth abnormalities,
such as increased proliferation of oligodendrocyte pre-
cursors in the embryonic spinal cord [157] and Schwann
cells [158]. Particularly, Nf1-/- and Nf1+/- NSCs generate
increased numbers of morphologically abnormal, imma-
ture astroglial cells in vitro [159]. The increase in astro-
glial progenitors and proliferating cells seen in vitro was
also observed in Nf1-/- and Nf1+/- embryonic brains and
Nf1+/- adult brains in vivo [159]. In addition, Lee and
colleagues showed that Nf1-/- NSCs from the brainstem
exhibit increased proliferation and glial cell differenti-
ation in vitro and in vivo; however, the lack of effect on
neocortex NSCs proliferation or gliogenesis suggests that
the effects of Nf1 gene inactivation are brain region-
specific [160].
What would be an underlying mechanism for the en-
hanced glial population in NF1? It has been demonstrated
that Nf1 inactivation in neural stem/progenitor cells can
alter glia/neuron fate specification by promoting the ex-
pression of Olig2, a basic-helix-loop-helix transcription
factor that is required for oligodendrocyte progenitor cell
specification [161]. Nf1hGFAP CKO and Nf1BLBP CKO mu-
tant mice showed increased Olig2 expression, suggesting
that Nf1 suppresses Olig2 expression and the oligodendro-
cyte progenitor lineage in neonatal subventricular zone
progenitor cells [85, 160]. In concordance with the neo-
natal study, inactivation of Nf1 in adult NSCs also resulted
in increased Olig2 expression [90]. In conclusion, these
studies with Nf1 mutant mice revealed the essential role
of NF1 in CNS development, including the gross morph-
ology and proper formation of several brain region struc-
tures, and the regulation of cell fate.
Along with structural abnormalities in CNS, several
lines of evidence suggest that the distribution of NF1 in
single neuronal cell type may also contribute to cognitive
deficits in NF1. Transcriptome analyses of mouse brain
have unveiled the enriched NF1 expression in inhibitory
neurons rather than the in excitatory neurons, and pro-
vided a clue as to how NF1 mainly carries out its role in
inhibitory synaptic function [162]. Furthermore, based on
the conserved expression pattern of NF1 in human brain,
it is suggested that the enriched expression of NF1 in in-
hibitory neurons may underlie cell type-specific patho-
physiology and cognitive deficits in NF1 [163].
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Nf1 mutant mice mimic most of the CNS features
found in NF1 human patients, including increased brain
volume, enlarged corpus callosum and cortical area, and
especially, enhanced gliogenesis, which may be closely
associated with structural abnormalities. Despite com-
pelling evidences of the expression of glial lineage tran-
scription factors such as Olig2 increasing as RAS-ERK
highly activates [85, 90, 108], yet it is unclear how RAS-
ERK pathway regulates cell fate determinants. Thus, for
understanding CNS abnormalities in NF1 patients, it is
worth investigating the expression regulations of cell fate
determinants with regard to RAS-ERK activity.
Noonan syndrome and Noonan syndrome with multiple
lentigines
Noonan syndrome (NS) is an autosomal dominant gen-
etic disorder with an incidence of 1 in 2,500 live births
[31, 164, 165]. This complex disorder occurs both in fa-
milial and sporadic forms [166]. Germline mutations in
genes involved in RAS-ERK signaling pathway have been
reported to be associated with NS, such as the gain of
function mutations in protein tyrosine phosphatase non-
receptor type 11 (PTPN11), son of sevenless homolog 1
(SOS1), Kirsten rat sarcoma viral oncogene homolog
(KRAS), neuroblastoma RAS viral oncogene homolog
(NRAS), Raf-1 proto-oncogene (RAF1), BRAF, soc-2 sup-
pressor of clear homolog (SHOC2), and MEK1, and the
loss of function mutations in Cbl proto-oncogene (CBL)
[25, 63, 167]. Above all, mutations in PTPN11, which en-
codes the non-receptor protein phosphatase SHP2, ac-
count for approximately 50% of NS cases [167]. Patients
with NS are characterized by typical facial abnormalities,
such as a broad forehead, sparse eyebrows, a low-set and
posteriorly rotated ear, and a webbed neck, while other
important features include a short stature, motor delay,
increased risk of cancer, and cardiac defects [34–40].
Noonan syndrome with multiple lentigines (NSML) pa-
tients have most of the clinical symptoms observed in
individuals with NS, but they also display increased
penetrance of hypertrophic cardiomyopathy and lentigi-
nes [168]. Distinct from NS, PTPN11 loss of function
mutations result in NSML [168].
Between 30%-50% of NS patients show a variable degree
of neurocognitive delay, but there are relatively few reports
of CNS malformations in NS individuals [34, 35]. Two
cases of NS were reported to be associated with cerebellar
ectopia [28, 29]. In addition, there are several reports of NS
being associated with a temporal lobe anomaly, hydroceph-
alus, cerebral abscess, and malignant Schwannoma [30–32].
In particular, Saito and colleagues reported one case of an
NS patient with severe mental retardation and intractable
epilepsy [33]. The patient also displayed cortical dysplasia,
including dilated perivascular spaces and a dysplastic lesion
in the left temporal lobe [33].
Mutant mice harboring NS-associated Sos1E846K,
KrasV14I, and Raf1L613V displayed a short stature, facial dys-
morphia, growth retardation, and cardiac defects, which are
characteristic features of NS patients [169–172]. Since
PTPN11 mutations are the majority among NS cases, Shp2
mutant mice are one of the most studied models of NS
[96–98, 173, 174]. A subpopulation of NS patients have a
constitutively active mutation Shp2D61G, which has a highly
increased phosphatase activity [175, 176]. The homozygous
Shp2D61G mutation was eventually embryonically lethal, as
the embryos were grossly hemorrhagic and edematous,
showed a decreased liver size, and had cardiac defects [98].
However, half of heterozygous Shp2D61G mice that carried
only one copy of the mutant allele (Shp2D61G/+) survived,
and displayed a short stature and craniofacial dysmorphia,
such as wide-set eyes, a broad forehead, and a triangular
face, which were similar to NS patients [98]. Heterozygous
Shp2D61G mice also showed deficits in spatial learning and
memory and had impaired synaptic plasticity [97]. Mice
carrying a milder mutation, Shp2N308D, displayed some car-
diac defects and mild impairment to spatial learning and
memory that was consistent with human cases [97, 98].
Neural crest cell-specific Shp2Q79R resulted in craniofacial
defects and growth retardation [170]. Neural stem cell-
specific expression of Shp2E76K by using Nestin-Cre re-
sulted in hydrocephalus due to aberrant development of
ependymal cells [95]. In addition, Shp2E76K-expressing mice
showed hyperactivity accompanied by reduced anxiety be-
havior, and impaired motor function [95]. Global Shp2D61Y
expression resulted in embryonic lethality, while epiblast-
specific Shp2D61Y expression induced embryonic cardiac
defects [173].
SHP2 is a growth factor-regulated phosphatase that
modulates both the RAS-ERK and the gp130-JAK-STAT
pathways [177, 178]. Since both pathways are known to
play critical roles in cell proliferation and differentiation,
several studies demonstrated that SHP2 affects cell pro-
liferation and differentiation in large range of cell types
[179–183]. For example, SHP2 is required for the initi-
ation of retinal neurogenesis and it regulates the pattern-
ing of optic vesicles by mediating retinal progenitor
factors and cell proliferation [184]. Huang and colleagues
have shown that the suppression of SHP2 activity reduces
cell migration and neurite outgrowth, and that it decreases
the differentiation-induced activation of FAK, Src, paxillin,
and ERK1/2 [185]. Also, the authors demonstrated that
SHP2 is recruited to focal adhesions in NSCs and that it
regulates focal adhesion formation [185].
Recent studies have suggested that Shp2 is involved in
oligodendrocyte development in the telencephalon. In
vitro studies using rat cortical cultures demonstrated dif-
ferent roles for Shp2 in either oligodendrocyte precursor
cell proliferation or maturation [186, 187]. The in vivo
function of Shp2 in oligodendrocyte differentiation was
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also investigated by Zhu and colleagues using condi-
tional mutant mice with a selective Shp2 deletion in
Olig1-expressing cells in the ventral spinal cord [93].
The mutant mice displayed a dramatic reduction in the
number of both oligodendrocyte precursor cells and ma-
ture oligodendrocytes and decreased axonal myelination
in the developing CNS, suggesting that Shp2 is a critical
regulator of oligodendrocyte proliferation and differenti-
ation [93]. Similarly, Ehrman and colleagues investigated
the role of Shp2 in ventricular zone progenitor cells of
the ventral telencephalon and in cells of the oligo-
dendrocyte lineage by deleting Shp2 in Olig2-positive
cells [94]. Olig2-specific Shp2 null mutant mice showed
a significant decrease in the number of oligodendrocyte
progenitor cells, at embryonic and postnatal stages, and
severe hypomyelination [94]. Moreover, expressing an
NS-associated mutation Shp2Q79R using Olig2-Cre in-
creased the number of oligodendrocyte precursor cells
in the embryonic and postnatal brain, but also induced
abnormal myelination and fewer myelinated axons in
the white matter [94].
SHP2 has been shown to play a role in cell fate deci-
sions as it promotes neurogenesis and suppresses astro-
gliogenesis through the repression of the JAK-STAT
pathway, which is required for astrocyte formation in
the developing brain. Gauthier and colleagues reported
that germline Shp2D61G heterozygous mice showed more
neurons and fewer astrocytes in the hippocampus and
dorsal cortex at postnatal day 2, and suggested that NS-
associated mutations cause brain abnormalities by dis-
rupting the balance of CNS populations [96]. Ke and
colleagues also demonstrated that SHP2 is an important
player in mammalian brain development by generating a
novel mutant mouse in which Shp2 is selectively elimi-
nated in neural precursor cells [92]. The mutant mouse
showed early postnatal lethality, decreased proliferation
of NSCs, and lamination defects in the developing cere-
bral cortex [92]. Mutant mice showed a reduced number
of neurons and an increased number of astrocytes,
which imply defective neuronal differentiation and mod-
estly enhanced astrogliogenesis, supporting the idea that
Shp2 promotes neurogenesis and suppresses astrocyto-
genesis [92]. The peripheral nervous system of Wnt1-
Cre or Krox20-Cre conditional Shp2 floxed mice dis-
played severe deficits in Schwann cell development and
the hypomyelination of peripheral nerves [188].
There are other NS mouse models in addition to Shp2
mutant mice. Heterozygous Raf1-deficient mice display
smaller granule cell layer volumes at postnatal day 30 and
a substantial number of abnormal, chromophilic, fast div-
iding cells in the subgranular zone and dentate gyrus
[105]. In addition, Raf1-deficient neural progenitor cells
showed an increased rate of cell death and reduced neur-
onal maturation [105]. Recently, Holter and colleagues
reported that mice expressing the NS-associated gain of
function mutation Raf1L613V have a significantly greater
density of GFAP-positive astrocytes in the cortex and
hippocampus. In addition, the number of Olig-positive
oligodendrocyte progenitor cells were also increased in
cortical area of Raf1L613V mutant mice [107]. Interestingly,
Raf1L613V mice showed enhanced performance in several
learning tasks [107]. NS-associated KrasG12V mutant mice
showed enhanced GABAergic synaptogenesis and im-
paired spatial learning when the mutation was selectively
expressed in synapses [99].
Although it is known that transcription factors for glial
lineage become highly expressed in accordance with in-
creasing RAS-ERK activity [85, 90, 108], RAS-activating
mutation SHP2D61G promotes neuronal lineage rather
than glial lineage, by direct interaction with JAK-STAT
pathway [96]; however, the expression of glial transcrip-
tion factors that may have been affected by the increase in
RAS-ERK activity is yet to be examined. On the contrary,
other NS-linked mutations such as Raf1L613V rather en-
hanced glial lineage [107]. Although the underlying mech-
anism for the discrepancy in cellular phenotypes is not
clear, these results suggest that there are distinct patho-
physiology according to each NS-associated mutation. It
would be interesting to examine the neuron-glia ratio in
either NS patient-derived iPSCs or postmortem brain tis-
sues harboring specific PTPN11 or RAF1 mutations.
Cardio-facio-cutaneous syndrome
Cardio-facio-cutaneous syndrome (CFCS) is a rare RASo-
pathy that is caused by mutations in the genes that encode
downstream effectors of RAS [41, 42, 44], including BRAF
[41, 42], KRAS [41], and MEK1/2 [42]. Importantly, het-
erozygous BRAF mutations are found in over 70% of
CFCS patients [58]. BRAF encodes a serine/threonine kin-
ase, and, interestingly, both the kinase-active and kinase-
impaired mutations of BRAF are associated with CFCS
[41, 42]. Heterozygous missense mutations in MEK1 and
MEK2 are found in approximately 25% of CFCS individ-
uals [58]. MEK1 and MEK2 are threonine/tyrosine ki-
nases, and all the MEK mutants associated with CFCS are
activating mutations [42, 189]. CFCS patients display mul-
tiple congenital abnormalities which overlap with those
seen in NS and Costello syndrome, including craniofacial
defects, hypertrophic cardiomyopathy, pulmonary artery
stenosis, and neurocognitive delay [58]. CFCS individuals
exhibit NS-like faces, with macrocephaly, low-set ears, a
short nose, a broad forehead, and down-slanting palpebral
fissures with ptosis [4, 59]. Cardiac abnormalities are also
similar to those of NS and Costello syndrome, with pul-
monic stenosis, septal defects, and hypertrophic cardiomy-
opathy (HCM) having the highest prevalence [59].
Neurological abnormalities, including hypotonia, motor
delay, seizures, tactile defensiveness, speech delay, and
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learning disabilities, are present at varying degrees
[4, 50, 55]. Failure to thrive caused by gastrointes-
tinal dysfunction, including vomiting, oral aversion,
reflux, and constipation, is also typical in CFCS individuals
in infancy [50]. However, CNS abnormalities are signifi-
cant diagnostic features of CFCS. Previous studies re-
ported the abnormalities in brain structures, including
ventriculomegaly and hydrocephalus, in CFCS patients
[44–50]. Volume loss in the brain due to cortical atrophy,
cerebral atrophy, brain stem atrophy, and white matter at-
rophy have also emerged in a subpopulation of patients
[44, 46, 51–54]. Additionally, migration abnormalities,
myelination abnormalities, and corpus callosum ab-
normalities, such as hypoplasia and lipoma were also
revealed by brain imaging [50, 52, 55–57]. In line
with brain abnormalities, most CFCS patients are di-
agnosed with varying degrees of cognitive deficits and
intellectual disabilities [50].
Recently, patient-derived induced pluripotent stem
cells (iPSCs) have contributed to advancements in the
understanding of disease-associated mutations. Yeh and
colleagues generated iPSC from a patient harboring
BRAFQ257R, the most frequent CFCS mutation [190].
This mutation resulted in a depletion of neural progeni-
tor pool, induced by decreased phosphorylation of AKT,
and early neuronal maturation [190]. Due to the deple-
tion of progenitors, the number of late-born cells, such
as the upper-layer cortical neurons and glia, was de-
creased [191]. The number of GABAergic interneurons
was increased, indicating that the high prevalence of sei-
zures in CFCS individuals may be caused by an imbal-
ance between excitation and inhibition [191].
Fewer animal models of CFCS have been reported
likely due to its lower prevalence (1 in 810,000) com-
pared to other RASopathies. Transgenic mouse models
carrying gain of function mutations that are associated
with CFCS recapitulate multiple aspects of human CFCS
patients [108, 192]. Since BRAF is the most prevalent
gene that is mutated in CFCS, a majority of animal stud-
ies in CFCS have focused on Braf. Prior to the review of
gain of function mouse models associated with CFCS,
we first reviewed loss of function studies that investi-
gated the role of Braf in various biological processes.
Wiese and colleagues identified that cultured embryonic
sensory and motor neurons lacking Braf could not sur-
vive in the presence of neurotrophic factors while Raf1-
deficient neurons could survive, suggesting that Braf is
essential for survival [193]. A Braf null mutant mouse
was embryonically lethal due to the vascular defects at
midgestation [194]. In addition, the ablation of Braf in
NSCs using Nestin-Cre resulted in abnormal morpho-
genesis of the CNS, such as a decreased cerebellum with
fuzzy granule cell layer borders and a diminished hippo-
campus granule cell layer, due to reduced differentiation
of dentate gyrus progenitor cells into mature granule cell
neurons [102]. Nestin-Cre specific Braf-deficient mice also
displayed severe dysmyelination and defective oligo-
dendrocyte differentiation, implicating Braf in postnatal
CNS development [103]. Forebrain excitatory neuron-
specific Braf knockout mice showed deficits in hippocam-
pal long-term potentiation and impaired hippocampal-
dependent learning and memory, while the impact of Braf
deletion on CNS development in this knockout remains
to be investigated [195].
The first mutant mouse model of CFCS was a knock-
in of the constitutively active form of Braf, BrafV600E,
which recapitulates several CFCS characteristics, includ-
ing a reduced life span, growth retardation, facial dys-
morphia, cardiomegaly, and epileptic seizures [104].
Mice expressing the conditional knock-in BrafL597V mu-
tation also recapitulated CFCS symptoms of a short stat-
ure, facial dysmorphia, and cardiac enlargement [196].
The most prevalent CFCS mutation, BrafQ241R, induced
embryonic/neonatal lethality with multiple congenital
defects that included embryonic skeletal abnormalities,
lymphatic defects, cardiac defects, and liver necrosis in
the C57BL/6J background, and lethality between birth
and 24 weeks, growth retardation, sparse and ruffled fur,
liver necrosis, and atrial septal defects on the mixed
background (BALB/c and C57BL/6J) [192, 197]. In
addition, BrafQ241R/- mice showed growth retardation, a
hunched appearance, craniofacial dysmorphism, and
learning deficits on ICR background [192].
Mouse models carrying Mek1Y130C, the most common
MEK1 mutation in CFCS patients, showed increased ERK
activation in response to growth factors, pulmonary artery
stenosis, cranial dysmorphia, and neurological anomalies
[108]. Moreover, Mek1Y130C/Y130C mice showed a higher
density of GFAP-positive astrocytes in the sensory cortex
and hippocampal CA1 regions [108]. In addition, the total
cortical oligodendrocyte population, as analyzed by Olig2
immunolabeling, was increased in the sensory cortex of
Mek1Y130C/Y130C mice [108]. As addressed earlier,
patients-derived iPSC containing BRAFQ257R exhibited
early neuronal maturation and decreased late-born glial
populations, whereas either CFCS-associated Mek1Y130C
or BrafV600E expressing adult mice exhibited an increased
number of GFAP-positive cells in hippocampal and cor-
tical areas [104, 108, 190]. Although, BRAFQ257R is a gain
of function mutation, the activation of ERK was decreased
in neural progenitor cells, which might have been due to
cell context-dependent role of BRAF, and these results in-
dicate that the decreased ERK activation may be respon-
sible for the decreased glia in BRAFQ257R iPSCs [190]. In
addition to mouse models, zebrafish models expressing
CFCS Braf or Mek variants were also generated, and these
CFCS mutant alleles interfered with convergence-
extension cell movements during gastrulation to cause
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similar developmental phenotypes [189]. Taken together,
each of the CFCS-associated genes play essential roles in
CNS development, including oligodendrocyte precursor
maturation and proliferation, myelination, and neuronal
differentiation. However, our knowledge regarding the
causal relationship between CNS abnormalities and cogni-
tion in CFCS is still limited. Further studies using mutant
animals with more specific temporal and spatial manipula-
tion of CFCS genes would provide understanding of the
pathophysiology of cognitive deficits in CFCS.
Costello syndrome
Costello syndrome (CS) is a rare multiple congenital ab-
normality syndrome that affects 1 in 1,250,000 people and
shares many features with other RASopathies [198–200].
CS is mostly caused by gain of function mutations in the
HRAS gene, most of which have been previously reported
as somatic or oncogenic mutations in various tumors
[60, 62, 201]. HRAS activating mutations are highly
prevalent in CS individuals; they disrupt guanine nucleo-
tide binding and induce a decrease in intrinsic and GAP-
induced GTPase activity, allowing mutant HRAS proteins
to remain in the active state [202]. In addition, BRAF,
KRAS, and MEK1 mutations are also associated with a
small population of CS individuals [27, 63, 203]. CS pa-
tients are typical characterized by coarse facial features, re-
dundant and loose skin, severe failure to thrive, mental
retardation, cardiomyopathy, and a predisposition to tu-
mors [59, 60]. There is no single feature that is unique to
CS, and this syndrome phenotypically overlaps with NF1,
NS, NSML, and CFCS [60, 204]. Typical and coarse facial
features associated with CS involve macrocephaly with a
prominent forehead, a short nose with a depressed nasal
bridge and a broad base, and low-set, posteriorly rotated
ears with thickened helices and lobes. Most CS patients
have cardiac abnormalities, including hypertrophic cardio-
myopathy, valve abnormalities, septal defects, and
arrhythmia [205]. Failure to thrive due to gastrointestinal
dysfunction often involves reflux, oral aversion, and con-
stipation during early infancy [67, 200]. Structural and
electrophysiological neurological malformations are also
common in CS. For example, ventricular abnormalities,
such as mild ventricular dilatation, are observed in more
than 40% of CS individuals [64–67]. Cerebral malforma-
tions in CS include cerebral atrophy, leukomalacia, poor
gray-white matter differentiation, a small corpus callosum,
and MRI signal abnormalities [64, 65, 67–71]. Cerebellar
abnormalities include malformation, cerebellar atrophy,
deviation of the cerebellar tonsils, and demyelinization of
the basal tonsil [66, 69, 71–74].
Krencik and colleagues have shown that human iPSCs
carrying HRASG12S that were derived from CS patients
exhibited hyperplasia and differentiated into astroglia
more rapidly in vitro than iPSCs derived from control
cell lines with normal HRAS. CS-derived iPSCs also gen-
erated an abundance of extracellular matrix remodeling
factors and proteoglycans [206]. Moreover, HRASG12S
iPSC-derived neurons had a longer progenitor phase,
unlike the phenotype reported in BRAFQ257R iPSC-
derived neurons that originated from CFCS patients
[190, 207]. Thus, postnatal progressive cerebellar over-
growth of the brain in CS individuals could be caused by
the extended progenitor phase [208].
As with CFCS, only few animal models were generated
for CS. Both homozygous and heterozygous HrasG12V
knock-in mice closely phenocopied some of the features
observed in individuals with CS, including facial dys-
morphia, cardiomyopathies, and alterations to the homeo-
stasis of the cardiovascular system [209]. In addition, later
studies with homozygous HrasG12V knock-in mice demon-
strated that they have neurocognitive deficits, such as
hyperactivity, increased anxiety-like behavior and mild
deficit in spatial memory [210]. However, Viosca and col-
leagues did not observe significant changes in either the
activity or the expression of downstream of Hras such as
phospho-CREB and c-fos [210]. Transgenic mice with
forebrain excitatory neuron-specific expression of
HrasG12V under the control of the αCaMKII promoter dis-
played several synaptic phenotypes, including a high dens-
ity of docked neurotransmitter vesicles in glutamatergic
terminals and increased synaptic plasticity which may be
associated with the dramatically enhanced hippocampal-
dependent learning [101]. Schreiber and colleagues have
also shown that the homozygous HrasG12V knock-in mice
exhibit spatial learning deficits, which are accompanied by
robust upregulation of Erk signaling in hippocampal ly-
sates, neuronal hypertrophy, increased brain volume, and
impaired mGluR-dependent long-term depression (LTD)
[100]. Notably, mice expressing CS-associated HrasG12V
or HrasG12S mutations in cortical precursors displayed
promoted precursor cell proliferation and premature glio-
genesis, but inhibited neurogenesis [211]. Consistently, ei-
ther form of Hras mutations also promoted precursor cell
proliferation and astrogenesis, but inhibited neurogenesis
in cultured cortical precursors [211]. These findings from
multiple experimental systems such as iPSCs, mice models
and cultured cells commonly suggest the essential role of
HRAS in neural precursor cell proliferation and gliogen-
esis, which might strongly affect the structure and func-
tion of CNS including increased brain volume in CS
patients.
Concluding remarks
Here, we reviewed that mutations in different compo-
nents of the RAS-ERK signaling pathway associated with
different RASopathies have distinct impacts on CNS de-
velopment in a cell type-specific manner (Fig. 2). How-
ever, it is still unclear how some mutations affect
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neurons and others affect glia. One hypothesis is that
different signaling molecules are expressed at distinct
phases during development. So far, we do not have the
expression profiles of RAS signaling molecules during
brain development in high spatial and temporal reso-
lution. However, most of the key RAS-ERK components,
such as NF1, SHP2, BRAF, and MEK1/2, begin to be
expressed before either embryonic day 10 or 15, which
are initiation time points of neurogenesis or astroglio-
genesis, respectively [212]. Recently, it has been shown
that the expression of RAS-ERK signaling molecules was
remarkably different between excitatory and inhibitory
neurons in mouse hippocampus [162]. Thus, it would be
interesting to examine whether the expression levels of
various signaling molecules are differentially regulated in
NSCs over different developmental stages. Advanced
tools, such as single cell RNA-seq, might be useful to
answer this question. It should also be considered that
there are multiple cross-talks between RAS and other
signaling pathways. Different components in RAS signal-
ing interact with distinct signaling networks, which may
account for the cell type-specific developmental deficits
in each RASopathy.
Treatments for the cognitive deficits found in RASopa-
thies are not available yet. Since most RASopathy-
associated mutations increase RAS-ERK activation, down-
regulating the activity of RAS or its downstream effectors
is an obvious strategy to develop treatments for RASopa-
thies. Although statins, which can reduce RAS activity by
inhibiting the farnesylation of RAS, have been proposed
for the improvement of learning disabilities in NF1 chil-
dren [213], the results from various clinical trials have
been inconsistent [214–216]. The reason for these dis-
crepant results remains unclear. However, considering the
Fig. 2 Effect of RAS signaling components on neural stem cell differentiation. Neural stem cells are able to generate progeny cells that terminally
differentiate into neurons, oligodendrocytes, and astrocytes. a NF1 inactivation led to decreased neurogenesis in neonatal and adult mouse
brains [85]. PTPN11 positively regulates neurogenesis at the expense of gliogenesis [96]. b NF1 negatively regulates gliogenesis, thus NF1
inactivation increases the number of glial progenitor cells and gliogenesis [78, 79, 85, 89, 159, 160]. PTPN11 suppresses gliogenesis by directly
interacting with the JAK-STAT pathway, which promotes gliogenesis [92, 96]. c Hyperactivation of RAF1 induces the increase of glial lineage
populations, including oligodendrocyte progenitor cells and astrocytes [107]. MEK is required for gliogenesis, and the hyperfunction of MEK1
leads to increase in glial populations [108, 109]. d BRAF and RAF1 positively regulate neuronal differentiation, and the disruption of BRAF or RAF1
impairs the ability of progenitor cells to differentiate into mature neurons in mouse brain [102, 105]. In consistent, iPSC containing hyperactivated
BRAF mutant showed early maturation of neurons [190]. e Oligodendroglial lineage potential is restricted by NF1 in the adult hippocampus, and
inactivation of NF1 allows the adult hippocampus to generate oligodendrocytes [85]. f BRAF is required for oligodendrocyte maturation and
myelination during postnatal development [103]. g Hyperactivated HRAS leads to an acceleration of astroglial maturation [206, 211]. Blue and red
arrows indicate positive and negative regulation, respectively.
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ubiquitous expression of RAS in many cell types and mul-
tiple organs, directly regulating RAS activity may have un-
known confounding effects. Thus, it would be better to
target specific molecules other than RAS in a disease-
specific manner. For example, Omrani and colleagues
showed that inhibitory neuron-specific attenuation of
hyperpolarization-activated cyclic nucleotide-gated (HCN)
currents can be an underlying mechanism for the cogni-
tive deficits in Nf1+/- mice when they used an HCN agon-
ist to rescue cognitive deficits in Nf1+/- mice [217].
Recently, Ryu and colleagues showed that selectively redu-
cing the interaction between mutant SHP2 and Gab1 in
excitatory neurons reversed the physiological and behav-
ioral deficits in a mouse model of NS [162]. Conditional
mutant mice with higher spatial and temporal resolution
will provide clues when, where, and which cell types are
most suited for interventions.
Lastly, it should be noted that most of the RASopathy
mechanism studies have used mice as a model system.
Mouse models have many advantages and can be used
to study neuropsychiatric disorders because the majority
of neuropsychiatric drugs used in humans were shown
to be, at least partially, effective in mouse models [218].
However, caution is still warranted. Nowadays, it has be-
come relatively easy to model diseases in vitro using
iPSC and several iPSC lines are available to study RASo-
pathies, allowing for parallel and comparative analyses
in vitro and in vivo.
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